Labeled nucleotide analogs having protein shields
US-2015330987-A1 · Nov 19, 2015 · US
US10428318B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10428318-B2 |
| Application number | US-201615579843-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 9, 2016 |
| Priority date | Jun 9, 2015 |
| Publication date | Oct 1, 2019 |
| Grant date | Oct 1, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides engineered enzymes of transsialidase and/or sialyl transferase activity that have increased regioselectivity and/or increased thermostability.
Opening claim text (preview).
The invention claimed is: 1. A mutated α2,6-transsialidase that comprises an amino acid sequence with at least 60% identity to SEQ ID No: 1, and further comprises at least one mutation selected from the group consisting of: at position 156, an amino acid selected from the group consisting of Ser, Thr, Cys, Tyr, Asn, Gln and Trp; at position 161, an amino acid selected from the group consisting of Ala, Val, Ile, Leu, Phe, Tyr, Trp and Gly; at position 180, an amino acid selected from the group consisting of Asp, Asn and Gln; at position 186, an amino acid selected from the group consisting of Val, Ile, Leu, Met, Phe, Tyr, Trp, Ser, Cys and Thr; at position 218, an amino acid selected from the group consisting of Val, Ile, Leu, Met, Phe, Tyr, Trp, Cys, Gly and Thr; at position 222, an amino acid selected from the group consisting of Gin, Asp, Glu, Cys, Thr, Phe, Tyr, Trp, Arg, Lys and His; at position 235, an amino acid selected from the group consisting of Arg, His, Ser, Cys, Ala, Val, Ile and Leu; at position 242, an amino acid selected from the group consisting of Arg, His and Lys; at position 261, an amino acid selected from the group consisting of His, Lys, Asp, Glu, Ala, Val, Leu and Phe; at position 315, an amino acid selected from the group consisting of Ser, Thr and Cys; at position 342, an amino acid selected from the group consisting of Ser and Cys, preferably Cys; at position 349, an amino acid selected from the group consisting of Ser, Thr and Cys; at position 350, an amino acid selected from the group consisting of Ser, Thr, Cys, Tyr, Trp and Phe; at position 356, an amino acid selected from the group consisting of Ala, Val, Ile, Leu, Phe and Trp; and/or at position 438, an amino acid selected from the group consisting of Arg, His and Lys, wherein said mutated α2,6-transsialidase has transsialidase and/or sialyltransferase activity with increased regioselectivity and/or increased thermostability compared to a parent α2,6-transsialidase without the mutation. 2. The mutated α2,6-transsialidase of claim 1 having an improved regioselectivity in a transsialidation reaction compared to a protein having an amino acid sequence which is identical to SEQ ID No: 1. 3. The mutated α2,6-transsialidase of claim 1 , wherein the amino acid sequence with at least 60% identity to of SEQ ID No: 1 is a sialyl transferase from P. leiognathi JT-SHIZ-119 or its Δ2-15 truncated variant, a sialyl transferase from P. leiagnathi JT-SHIZ-145 or its Δ2-15 truncated variant, or a sialyl transferase from P. damselae JT0160 or its Δ2-15 truncated variant. 4. The mutated α2,6-transsialidase of claim 1 , wherein the at least one mutation is selected from the group consisting of: at position 156 Gly is substituted by Ser, Thr, Cys, Tyr, Asn, Gln or Trp; at position 161 Gln or Pro is substituted by Ala, Val, Ile, Leu, Phe, Trp or Gly; at position 180 Glu is substituted by Asp, Asn, Gln; at position 186 Ala or Gly is substituted by Val, Ile, Leu, Met, Phe, Tyr, Trp, Ser, Cys or Thr; at position 218 Ala or Ser is substituted by Val, Ile, Le et, Phe, Tyr, Trp, Cys, Gly or Thr; at position 222 Asn or Ser is substituted by Gln, Asp, Glu, Cys, Thr, Phe, Tyr, Trp, Arg, Lys or His; at position 235 Lys or Thr is substituted by Arg, His, Ser, Cys, Ala, Val, Ile or Leu; at position 242 Val or Leu is substituted by Arg, His or Lys; at position 261 Arg or Ile is substituted by His, Lys, Asp, Glu, Ala, Val, Leu or Phe; at position 315 Leu is substituted by Ser, Thr or Cys; at position 342 Thr is substituted by Ser or Cys; at position 349 Gly is substituted by Ser, Thr or Cys at position 350 Gly is substituted by Ser, Thr, Cys, Tyr, Trp or Phe; at position 356 Tyr is substituted by Ala, Val, Ile, Leu, Phe or Trp; and at position 438 Pro is substituted by Arg, His or Lys. 5. The mutated α2,6-transsialidase of claim 4 , wherein the amino acid sequence with at least 60% identity to SEQ No: 1 is a sialyl transferase from P. leiognathe JT-SHIZ-119 or its Δ2-15 truncated variant, and the at least one mutation is selected from the group consisting of: at position 156 Gly is substituted by Ser, Cys or Tyr; at position 161 Gln is substituted by Phe or Gly; at position 180 Glu is substituted by Asp, at position 186 Ala is substituted by Tyr, Cys or Leu; at position 218 Ala is substituted by Ile, Val, Phe or Tyr; at position 222 Asn is substituted by Cys, Asp, Arg or Phe; at position 235 Lys is substituted by Arg, His, Cys or Val; at position 242 Val is substituted by His; at position 261 Arg is substituted by Asp, Phe, His or Val; at position 315 Leu is substituted by Cys; at position 342 Thr is substituted by Cys; at position 349 Gly is substituted by Ser or Cys; at position 350 Gly is substituted by Ser, Tyr, Phe or Cys; at position 356 Tyr is substituted by Val or Phe; and at position 438 Pro is substituted by His. 6. The mutated α2,6-transsialidase of claim 1 , wherein the at least one mutation comprises at least two mutations at amino acid positions selected from the group consisting of: 156, 218, 222 and 349. 7. The mutated α2,6-transsialidase of claim 6 , wherein the at least two mutations comprises at least three mutations at amino acid positions selected from the group consisting of: 156, 218, 222 and 349. 8. The mutated α2,6-transsialidase of claim 1 , wherein the at least one mutation comprises the mutations of A218Y, N222R and G349S. 9. The mutated α2,6-transsialidase of claim 1 , further comprising a mutation at amino acid position 353, 400 or 450-458. 10. The mutated α2,6-transsialidase of claim 9 , wherein the at least one mutation comprises the mutations of A218Y, N222R and G349S, and the mutation at amino acid position 353, 400 or 450-458 comprises at least one mutation selected from the group consisting of: K353I, S400Y, S412P, D451K, D451L, D451M, T452V, D458R and D458F. 11. The mutated α2,6-transsialidase of claim 10 , wherein the mutation at amino acid position 353, 400 or 450-458 comprises mutations of S412P and D451K. 12. The mutated α2,6-transsialidase of claim 1 , wherein the mutated α2,6-transsialidase has sialyl transferase activity. 13. A process for making a mutated α2,6-transsialidase of claim 1 comprising the steps of: a) providing a DNA sequence encoding the mutated α2,6-transsialidase, then b) expressing the mutated α2,6-transsialidase in a host cell transformed with the DNA sequence obtained in step a). 14. A method for synthesizing a sialylated saccharide or glycoconjugate comprising the step of reacting a sialyl donor and a saccharide or glycoconjugate as acceptor in the presence of the α2,6-transsialidase according to claim 1 to transfer the sialyl residue of the sialyl donor to the saccharide or glycoconjugate acceptor. 15. The method of claim 14 , wherein the acceptor is an oligosaccharide or a glycoconjugate comprising an oligosaccharide having a galactosyl residue. 16. The method of claim 15 , wherein the sialyl residue is transferred by the mutated α2,6-transsialidase to attach it to the 6-position of the galactosyl residue. 17. The method of claim 16 resulting in the formation of a sialylated human milk oligosaccharide having a galactosyl residue to which a sialyl residue is attached with an α2-6 linkage. 18. The method of claim 17 , wherein the galactosyl residue in the said human milk oligosaccharide is a part of a N-acetyl-lactosaminyl residue. 19. The method of claims 17 , wherein the human milk oligosaccharide is 6′-SL, LST c, FLST c, SLNH, SLNnH-I, SLNnH
Transferases (2.) (ribonucleases C12N9/22) · CPC title
produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins · CPC title
Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds · CPC title
Glycopeptides, glycoproteins · CPC title
Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.